Overview
Indications
Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. DOSAGE AND ADMINISTRATION This fixed combination drug is not indicated for the initial therapy of hypertension (see ). WARNINGS - Neutropenia/Agranulocytosis In using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patie
Boxed Warning
FDA Black Box Warning
• When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible. • Fetal Toxicity Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS:) .
Contraindications
When this intervention should not be used
Trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients who are hypersensitive to any ACE inhibitor or verapamil. Because of the verapamil component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in: Because of the tra
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
9 trials linked to this intervention
Recent Trials
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Trandolapril (substance)
- SNOMED CT
- 386871006
- UMLS CUI
- C0076891
- RxNorm CUI
- 38454
- Labeler
- Glenmark Pharmaceuticals Inc., USA
Clinical Data
This intervention maps to 10 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.